Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Psychosis in Parkinson’s Disease: Looking Beyond Dopaminergic Treatments

Author(s): Milagros Rojas*, Mervin Chávez-Castillo, Pablo Duran, Ángel Ortega, María Judith Bautista-Sandoval, Juan Salazar, Manuel Riaño-Garzón, Maricarmen Chacín, Oscar Medina-Ortiz, Jim Palmar, Lorena Cudris-Torres and Valmore Bermúdez

Volume 28, Issue 33, 2022

Published on: 21 September, 2022

Page: [2725 - 2741] Pages: 17

DOI: 10.2174/1381612828666220428102802

Price: $65

Abstract

Background: Parkinson’s disease (PD) is the second most common neurodegenerative disorder worldwide. The symptoms of PD are characterized not only by motor alterations but also by a spectrum of nonmotor symptoms. Some of these are psychiatric manifestations such as sleep disorders; depression; cognitive difficulties that can evolve into dementia; and symptoms of psychosis, which include hallucinations, illusions, and delusions. Parkinson’s disease psychosis (PDP) occurs in 18-50% of patients with PD. Treating PDP is challenging because antipsychotic drugs tend to be inefficient or may even worsen the disease's motor symptoms.

Objective: This review aims to summarize the current understanding of the molecular mechanisms involved in PDP and recent innovative alternatives for its treatment.

Methods: This is a narrative review in which an extensive literature search was performed on the Scopus, EMBASE, PubMed, ISI Web of Science, and Google Scholar databases from inception to August 2021. The terms “Parkinson’s disease psychosis”, “Parkinson psychosis,” “neurodegenerative psychosis”, and “dopamine psychosis” were among the keywords used in the search.

Results: Recently, views on the etiology of hallucinations and illusions have evolved remarkably. PDP has been cemented as a multifactorial entity dependent on extrinsic and novel intrinsic mechanisms, including genetic factors, neurostructural alterations, functional disruptions, visual processing disturbances, and sleep disorders. Consequently, innovative pharmacological and biological treatments have been proposed. Pimavanserin, a selective 5-HT2A inverse agonist, stands out after its approval to treat PDP-associated hallucinations and illusions.

Conclusion: Future results from upcoming clinical trials should further characterize the role of this drug in the management of PDP as well as other treatment options with novel mechanisms of action, such as saracatinib, SEP-363856, cannabidiol, electroconvulsive therapy, and transcranial magnetic stimulation.

Keywords: Parkinson’s disease, psychosis, antipsychotics, visual hallucinations, illusions, delusions, pimavanserin, electroconvulsive therapy.

« Previous Next »
[1]
Marras C, Beck JC, Bower JH, et al. Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Dis 2018; 4(1): 21.
[http://dx.doi.org/10.1038/s41531-018-0058-0] [PMID: 30003140]
[2]
Dorsey ER, Elbaz A, Nichols E, et al. Global, regional, and national burden of Parkinson’s disease, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17(11): 939-53.
[http://dx.doi.org/10.1016/S1474-4422(18)30295-3] [PMID: 30287051]
[3]
Lewin Group. The economic burden of Parkinson’s Disease Michael J Fox Foundation for Parkinson’s Research Available from: https://www.michaeljfox.org/news/study-finds-parkinsons-52-billion-economic-burden-double-previous-estimates (Accessed on 2021 Jul 18).
[4]
Jankovic J. Parkinson’s disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008; 79(4): 368-76.
[http://dx.doi.org/10.1136/jnnp.2007.131045] [PMID: 18344392]
[5]
Hirano S. Clinical implications for dopaminergic and functional neuroimage research in cognitive symptoms of Parkinson’s disease. Mol Med 2021; 27(1): 40.
[http://dx.doi.org/10.1186/s10020-021-00301-7] [PMID: 33858320]
[6]
He Y, Tian Y, Han H, et al. The path linking disease severity and cognitive function with quality of life in Parkinson’s disease: The mediating effect of activities of daily living and depression. Health Qual Life Outcomes 2021; 19(1): 92.
[http://dx.doi.org/10.1186/s12955-021-01740-w] [PMID: 33731129]
[7]
Poewe W. Non-motor symptoms in Parkinson’s disease. Eur J Neurol 2008; 15(S1): 14-20.
[http://dx.doi.org/10.1111/j.1468-1331.2008.02056.x] [PMID: 18353132]
[8]
Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 2010; 67(8): 996-1001.
[http://dx.doi.org/10.1001/archneurol.2010.166] [PMID: 20697051]
[9]
Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003; 18(5): 510-4.
[http://dx.doi.org/10.1002/mds.10374] [PMID: 12722164]
[10]
Divac N, Stojanović R, Vujović SK, Medić B, Damjanović A, Prostran M. The efficacy and safety of antipsychotic medications in the treatment of psychosis in patients with parkinson’s disease. Behav Neurol 2016; 2016: 4938154.
[http://dx.doi.org/10.1155/2016/4938154] [PMID: 27504054]
[11]
Jethwa KD, Onalaja OA. Antipsychotics for the management of psychosis in Parkinson’s disease: Systematic review and meta-analysis. BJPsych Open 2015; 1(1): 27-33.
[http://dx.doi.org/10.1192/bjpo.bp.115.000927] [PMID: 27703720]
[12]
Gómez-Chavarín M, Roldan-Roldan G, Morales-Espinosa R, Pérez-Soto G, Torner-Aguilar C. Mecanismos fisiopatológicos involucrados en la enfermedad de Parkinson. Arch Neurocienc 2012; 17(1): 25-33.
[13]
Hinkle JT, Perepezko K, Bakker CC, et al. Onset and remission of psychosis in parkinson’s disease: Pharmacologic and motoric markers. Mov Disord Clin Pract (Hoboken) 2018; 5(1): 31-8.
[http://dx.doi.org/10.1002/mdc3.12550] [PMID: 29756003]
[14]
Taddei RN, Cankaya S, Dhaliwal S, Chaudhuri KR. Management of psychosis in Parkinson’s disease: Emphasizing clinical subtypes and pathophysiological mechanisms of the condition. Park Dis 2017; 2017: 3256542.
[http://dx.doi.org/10.1155/2017/3256542] [PMID: 29104810]
[15]
Bergman H, Deuschl G. Pathophysiology of Parkinson’s disease: From clinical neurology to basic neuroscience and back. Mov Disord 2002; 17(S3): S28-40.
[http://dx.doi.org/10.1002/mds.10140] [PMID: 11948753]
[16]
Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinical implications. N Engl J Med 1988; 318(14): 876-80.
[http://dx.doi.org/10.1056/NEJM198804073181402] [PMID: 3352672]
[17]
Blesa J, Trigo-Damas I, Dileone M, Del Rey NL-G, Hernandez LF, Obeso JA. Compensatory mechanisms in Parkinson’s disease: Circuits adaptations and role in disease modification. Exp Neurol 2017; 298((Pt B)): 148-61.
[18]
Navntoft CA, Dreyer JK. How compensation breaks down in Parkinson’s disease: Insights from modeling of denervated striatum. Mov Disord 2016; 31(3): 280-9.
[http://dx.doi.org/10.1002/mds.26579] [PMID: 26890687]
[19]
Antkiewicz-Michaluk L. Endogenous risk factors in Parkinson’s disease: Dopamine and tetrahydroisoquinolines. Pol J Pharmacol 2002; 54(6): 567-72.
[PMID: 12866710]
[20]
Emamzadeh FN, Surguchov A. Parkinson’s disease: Biomarkers, treatment, and risk factors. Front Neurosci 2018; 12: 612.
[http://dx.doi.org/10.3389/fnins.2018.00612] [PMID: 30214392]
[21]
Parent A, Hazrati LN. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 1995; 20(1): 91-127.
[http://dx.doi.org/10.1016/0165-0173(94)00007-C] [PMID: 7711769]
[22]
Yelnik J. Modeling the organization of the basal ganglia. Rev Neurol (Paris) 2008; 164(12): 969-76.
[http://dx.doi.org/10.1016/j.neurol.2008.04.019] [PMID: 18808769]
[23]
Beaulieu J-M, Espinoza S, Gainetdinov RR. Dopamine receptors - IUPHAR Review 13. Br J Pharmacol 2015; 172(1): 1-23.
[http://dx.doi.org/10.1111/bph.12906] [PMID: 25671228]
[24]
Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: From structure to function. Physiol Rev 1998; 78(1): 189-225.
[http://dx.doi.org/10.1152/physrev.1998.78.1.189] [PMID: 9457173]
[25]
Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci 2000; 23(10): S64-70.
[http://dx.doi.org/10.1016/S1471-1931(00)00019-7] [PMID: 11052222]
[26]
Sokoloff P, Diaz J, Le Foll B, et al. The dopamine D3 receptor: A therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006; 5(1): 25-43.
[http://dx.doi.org/10.2174/187152706784111551] [PMID: 16613552]
[27]
Beaulieu J-M, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011; 63(1): 182-217.
[http://dx.doi.org/10.1124/pr.110.002642] [PMID: 21303898]
[28]
Joseph JD, Wang Y-M, Miles PR, et al. Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors. Neuroscience 2002; 112(1): 39-49.
[http://dx.doi.org/10.1016/S0306-4522(02)00067-2] [PMID: 12044470]
[29]
Sibley DR, Monsma FJ Jr. Molecular biology of dopamine receptors. Trends Pharmacol Sci 1992; 13(2): 61-9.
[http://dx.doi.org/10.1016/0165-6147(92)90025-2] [PMID: 1561715]
[30]
Obeso JA, Rodríguez-Oroz MC, Benitez-Temino B, et al. Functional organization of the basal ganglia: Therapeutic implications for Parkinson’s disease. Mov Disord 2008; 23(S3): S548-59.
[http://dx.doi.org/10.1002/mds.22062] [PMID: 18781672]
[31]
Freeze BS, Kravitz AV, Hammack N, Berke JD, Kreitzer AC. Control of basal ganglia output by direct and indirect pathway projection neurons. J Neurosci 2013; 33(47): 18531-9.
[http://dx.doi.org/10.1523/JNEUROSCI.1278-13.2013] [PMID: 24259575]
[32]
Shrivastava AN, Triller A, Sieghart W. GABA(A) Receptors: Post-Synaptic Co-localization and cross-talk with other receptors. Front Cell Neurosci 2011; 5: 7.
[http://dx.doi.org/10.3389/fncel.2011.00007] [PMID: 21734865]
[33]
Galvan A, Devergnas A, Wichmann T. Alterations in neuronal activity in basal ganglia-thalamocortical circuits in the Parkinsonian state. Front Neuroanat 2015; 9: 5.
[http://dx.doi.org/10.3389/fnana.2015.00005] [PMID: 25698937]
[34]
Reeve A, Simcox E, Turnbull D. Ageing and Parkinson’s disease: Why is advancing age the biggest risk factor? Ageing Res Rev 2014; 14: 19-30.
[http://dx.doi.org/10.1016/j.arr.2014.01.004] [PMID: 24503004]
[35]
Willis AW, Evanoff BA, Lian M, et al. Metal emissions and urban incident Parkinson disease: A community health study of Medicare beneficiaries by using geographic information systems. Am J Epidemiol 2010; 172(12): 1357-63.
[http://dx.doi.org/10.1093/aje/kwq303] [PMID: 20959505]
[36]
Dick FD, De Palma G, Ahmadi A, et al. Environmental risk factors for Parkinson’s disease and parkinsonism: The Geoparkinson study. Occup Environ Med 2007; 64(10): 666-72.
[http://dx.doi.org/10.1136/oem.2006.027003] [PMID: 17332139]
[37]
Subramaniam SR, Chesselet M-F. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Prog Neurobiol 2013; 106-107: 17-32.
[http://dx.doi.org/10.1016/j.pneurobio.2013.04.004] [PMID: 23643800]
[38]
Ferreira SA, Romero-Ramos M. Microglia response during parkinson’s disease: Alpha-synuclein intervention. Front Cell Neurosci 2018; 12: 247.
[http://dx.doi.org/10.3389/fncel.2018.00247] [PMID: 30127724]
[39]
Atkin G, Paulson H. Ubiquitin pathways in neurodegenerative disease. Front Mol Neurosci 2014; 7: 63.
[http://dx.doi.org/10.3389/fnmol.2014.00063] [PMID: 25071440]
[40]
Park J-S, Blair NF, Sue CM. The role of ATP13A2 in Parkinson’s disease: Clinical phenotypes and molecular mechanisms. Mov Disord 2015; 30(6): 770-9.
[http://dx.doi.org/10.1002/mds.26243] [PMID: 25900096]
[41]
Lin MK, Farrer MJ. Genetics and genomics of Parkinson’s disease. Genome Med 2014; 6(6): 48.
[http://dx.doi.org/10.1186/gm566] [PMID: 25061481]
[42]
Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med 2012; 2(1): a008888.
[http://dx.doi.org/10.1101/cshperspect.a008888] [PMID: 22315721]
[43]
Wakabayashi K, Tanji K, Odagiri S, Miki Y, Mori F, Takahashi H. The Lewy body in Parkinson’s disease and related neurodegenerative disorders. Mol Neurobiol 2013; 47(2): 495-508.
[http://dx.doi.org/10.1007/s12035-012-8280-y] [PMID: 22622968]
[44]
Shults CW. Lewy bodies. Proc Natl Acad Sci USA 2006; 103(6): 1661-8.
[http://dx.doi.org/10.1073/pnas.0509567103] [PMID: 16449387]
[45]
Wakabayashi K, Tanji K, Mori F, Takahashi H. The Lewy body in Parkinson’s disease: Molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 2007; 27(5): 494-506.
[http://dx.doi.org/10.1111/j.1440-1789.2007.00803.x] [PMID: 18018486]
[46]
Jellinger KA. Dementia with Lewy bodies and Parkinson’s disease-dementia: Current concepts and controversies. J Neural Transm Vienna Austria 1996 2018; 125(4): 615-50.
[47]
Jellinger KA, Korczyn AD. Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease? BMC Med 2018; 16(1): 34.
[http://dx.doi.org/10.1186/s12916-018-1016-8] [PMID: 29510692]
[48]
Sogabe S, Yagasaki Y, Onozawa K, Kawakami Y. Mesocortical dopamine system modulates mechanical nociceptive responses recorded in the rat prefrontal cortex. BMC Neurosci 2013; 14(1): 65.
[http://dx.doi.org/10.1186/1471-2202-14-65] [PMID: 23815681]
[49]
Arias-Carrión O, Stamelou M, Murillo-Rodríguez E, Menéndez-González M, Pöppel E. Dopaminergic reward system: A short integrative review. Int Arch Med 2010; 3(1): 24.
[http://dx.doi.org/10.1186/1755-7682-3-24] [PMID: 20925949]
[50]
Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001; 22(6): 724-63.
[http://dx.doi.org/10.1210/edrv.22.6.0451] [PMID: 11739329]
[51]
Wang G-J, Volkow ND, Thanos PK, Fowler JS. Imaging of brain dopamine pathways: Implications for understanding obesity. J Addict Med 2009; 3(1): 8-18.
[http://dx.doi.org/10.1097/ADM.0b013e31819a86f7] [PMID: 21603099]
[52]
Tarazi FI. Neuropharmacology of dopamine receptors: Implications in neuropsychiatric diseases. J Sci Res Med Sci 2001; 3(2): 93-104.
[PMID: 24019715]
[53]
Belujon P, Grace AA. Dopamine system dysregulation in major depressive disorders. Int J Neuropsychopharmacol 2017; 20(12): 1036-46.
[http://dx.doi.org/10.1093/ijnp/pyx056] [PMID: 29106542]
[54]
Juri CC, Chaná CP. Levodopa for Parkinson’s disease: What have we learned? Rev Med Chil 2006; 134(7): 893-901.
[PMID: 17130974]
[55]
Lerner RP, Francardo V, Fujita K, et al. Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia. Sci Rep 2017; 7(1): 16005.
[http://dx.doi.org/10.1038/s41598-017-16228-1] [PMID: 29167476]
[56]
Montioli R, Voltattorni CB, Bertoldi M. Parkinson’s disease: Recent updates in the identification of human dopa decarboxylase inhibitors. Curr Drug Metab 2016; 17(5): 513-8.
[http://dx.doi.org/10.2174/138920021705160324170558] [PMID: 27025882]
[57]
Rangel-Barajas C, Coronel I, Florán B. Dopamine receptors and neurodegeneration. Aging Dis 2015; 6(5): 349-68.
[http://dx.doi.org/10.14336/AD.2015.0330] [PMID: 26425390]
[58]
Borovac JA. Side effects of a dopamine agonist therapy for Parkinson’s disease: A mini-review of clinical pharmacology. Yale J Biol Med 2016; 89(1): 37-47.
[PMID: 27505015]
[59]
Sampaio C, Bronzova J, Hauser RA, et al. Pardoprunox in early Parkinson’s disease: Results from 2 large, randomized double-blind trials. Mov Disord 2011; 26(8): 1464-76.
[http://dx.doi.org/10.1002/mds.23590] [PMID: 21542016]
[60]
Beitz JM. Parkinson’s disease: A review. Front Biosci Sch Ed 2014; 6: 65-74.
[61]
Kvernmo T, Härtter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006; 28(8): 1065-78.
[http://dx.doi.org/10.1016/j.clinthera.2006.08.004] [PMID: 16982285]
[62]
Cánovas AA, Piudo LR, Ruiz-Espiga GP, et al. Dopaminergic agonists in Parkinson’s disease. Neurologia 2014; 29(4): 230-41.
[http://dx.doi.org/10.1016/j.nrl.2011.04.012] [PMID: 21724302]
[63]
Stocchi F, Arnold G, Onofrj M, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004; 63(4): 746-8.
[http://dx.doi.org/10.1212/01.WNL.0000134672.44217.F7] [PMID: 15326260]
[64]
Meiser J, Weindl D, Hiller K. Complexity of dopamine metabolism. Cell Commun Signal 2013; 11(1): 34.
[http://dx.doi.org/10.1186/1478-811X-11-34] [PMID: 23683503]
[65]
Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: A review. JAMA 2014; 311(16): 1670-83.
[http://dx.doi.org/10.1001/jama.2014.3654] [PMID: 24756517]
[66]
Korchounov A, Meyer MF, Krasnianski M. Postsynaptic nigrostriatal dopamine receptors and their role in movement regulation. J Neural Transm Vienna Austria 1996 2010; 117(12): 1359-69.
[67]
Ávila A, Cardona X, Bello J, Maho P, Sastre F, Martín-Baranera M. Impulse control disorders and punding in Parkinson's disease: The need for a structured interview. Neurologia 2011; 26(3): 166-72.
[http://dx.doi.org/10.1016/j.nrl.2010.09.007] [PMID: 21163239]
[68]
Cannas A, Solla P, Floris G, Tacconi P, Marrosu F, Marrosu MG. Othello syndrome in Parkinson disease patients without dementia. Neurologist 2009; 15(1): 34-6.
[http://dx.doi.org/10.1097/NRL.0b013e3181883dd4] [PMID: 19131855]
[69]
Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov Disord 2005; 20(5): 523-39.
[http://dx.doi.org/10.1002/mds.20464] [PMID: 15818599]
[70]
Wolf E, Seppi K, Katzenschlager R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord 2010; 25(10): 1357-63.
[http://dx.doi.org/10.1002/mds.23034] [PMID: 20198649]
[71]
Sawada H, Oeda T, Yamamoto K, et al. Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: A retrospective cohort study. BMC Neurol 2013; 13(1): 145.
[http://dx.doi.org/10.1186/1471-2377-13-145] [PMID: 24119306]
[72]
Ecker D, Unrath A, Kassubek J, Sabolek M. Dopamine Agonists and their risk to induce psychotic episodes in Parkinson’s disease: A case-control study. BMC Neurol 2009; 9(1): 23.
[http://dx.doi.org/10.1186/1471-2377-9-23] [PMID: 19515253]
[73]
Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev 2008; (2): CD006564.
[http://dx.doi.org/10.1002/14651858.CD006564.pub2] [PMID: 18425954]
[74]
Müller T. Drug therapy in patients with Parkinson’s disease. Transl Neurodegener 2012; 1(1): 10.
[http://dx.doi.org/10.1186/2047-9158-1-10] [PMID: 23211041]
[75]
Xu W-J, Wei N, Xu Y, Hu S-H. Does amantadine induce acute psychosis? A case report and literature review. Neuropsychiatr Dis Treat 2016; 12: 781-3.
[http://dx.doi.org/10.2147/NDT.S101569] [PMID: 27103808]
[76]
Goldman JG, Vaughan CL, Goetz CG. An update expert opinion on management and research strategies in Parkinson’s disease psychosis. Expert Opin Pharmacother 2011; 12(13): 2009-24.
[http://dx.doi.org/10.1517/14656566.2011.587122] [PMID: 21635198]
[77]
Zahodne LB, Fernandez HH. Course, prognosis, and management of psychosis in Parkinson’s disease: Are current treatments really effective? CNS Spectr 2008; 13(3) (Suppl. 4): 26-33.
[http://dx.doi.org/10.1017/S1092852900017296] [PMID: 18323764]
[78]
Psychosis in Parkinson’s disease. Ann Indian Acad Neurol 2011; 14 (Suppl. 1): S16-7.
[PMID: 21847320]
[79]
Nagy H, Levy-Gigi E, Somlai Z, Takáts A, Bereczki D, Kéri S. The effect of dopamine agonists on adaptive and aberrant salience in Parkinson’s disease. Neuropsychopharmacology 2012; 37(4): 950-8.
[http://dx.doi.org/10.1038/npp.2011.278] [PMID: 22089321]
[80]
de la Riva P, Smith K, Xie SX, Weintraub D. Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurology 2014; 83(12): 1096-103.
[http://dx.doi.org/10.1212/WNL.0000000000000801] [PMID: 25128183]
[81]
Moskovitz C, Moses H III, Klawans HL. Levodopa-induced psychosis: A kindling phenomenon. Am J Psychiatry 1978; 135(6): 669-75.
[http://dx.doi.org/10.1176/ajp.135.6.669] [PMID: 655276]
[82]
Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res 2011; 221(2): 564-73.
[http://dx.doi.org/10.1016/j.bbr.2009.12.048] [PMID: 20060022]
[83]
Chang A, Fox SH. Psychosis in Parkinson’s disease: Epidemiology, Pathophysiology, and Management. Drugs 2016; 76(11): 1093-118.
[http://dx.doi.org/10.1007/s40265-016-0600-5] [PMID: 27312429]
[84]
Stansley BJ, Yamamoto BK. L-dopa and brain serotonin system dysfunction. Toxics 2015; 3(1): 75-88.
[http://dx.doi.org/10.3390/toxics3010075] [PMID: 29056652]
[85]
Wolters EC. Intrinsic and extrinsic psychosis in Parkinson’s disease. J Neurol 2001; 248(S3): III22-7.
[http://dx.doi.org/10.1007/PL00007822] [PMID: 11697684]
[86]
Morgante L, Colosimo C, Antonini A, et al. Psychosis associated to Parkinson’s disease in the early stages: Relevance of cognitive decline and depression. J Neurol Neurosurg Psychiatry 2012; 83(1): 76-82.
[http://dx.doi.org/10.1136/jnnp-2011-300043] [PMID: 21836035]
[87]
Goetz CG, Pappert EJ, Blasucci LM, et al. Intravenous levodopa in hallucinating Parkinson’s disease patients: High-dose challenge does not precipitate hallucinations. Neurology 1998; 50(2): 515-7.
[http://dx.doi.org/10.1212/WNL.50.2.515] [PMID: 9484386]
[88]
Dotchin CL, Jusabani A, Walker RW. Non-motor symptoms in a prevalent population with Parkinson’s disease in Tanzania. Parkinsonism Relat Disord 2009; 15(6): 457-60.
[http://dx.doi.org/10.1016/j.parkreldis.2008.11.013] [PMID: 19196538]
[89]
Pagonabarraga J, Martinez-Horta S, Fernández de Bobadilla R, et al. Minor hallucinations occur in drug-naive Parkinson’s disease patients, even from the premotor phase. Mov Disord 2016; 31(1): 45-52.
[http://dx.doi.org/10.1002/mds.26432] [PMID: 26408291]
[90]
Widge AS, Agarwal P, Giroux M, Farris S, Kimmel RJ, Hebb AO. Psychosis from subthalamic nucleus deep brain stimulator lesion effect. Surg Neurol Int 2013; 4(1): 7.
[http://dx.doi.org/10.4103/2152-7806.106265] [PMID: 23493632]
[91]
Larson PS. Deep brain stimulation for movement disorders. Neurother J Am Soc Exp Neurother 2014; 11(3): 465-74.
[http://dx.doi.org/10.1007/s13311-014-0274-1] [PMID: 24833244]
[92]
Hickey P, Stacy M. Deep brain stimulation: a paradigm shifting approach to treat parkinson’s disease. Front Neurosci 2016; 10: 173.
[http://dx.doi.org/10.3389/fnins.2016.00173] [PMID: 27199637]
[93]
Volkmann J, Herzog J, Kopper F, Deuschl G. Introduction to the programming of deep brain stimulators. Mov Disord 2002; 17(S3): S181-7.
[http://dx.doi.org/10.1002/mds.10162] [PMID: 11948775]
[94]
Qureshi AA, Cheng JJ, Sunshine AN, et al. Postoperative symptoms of psychosis after deep brain stimulation in patients with Parkinson’s disease. Neurosurg Focus 2015; 38(6): E5.
[http://dx.doi.org/10.3171/2015.3.FOCUS1523] [PMID: 26030705]
[95]
Paleacu D, Schechtman E, Inzelberg R. Association between family history of dementia and hallucinations in Parkinson disease. Neurology 2005; 64(10): 1712-5.
[http://dx.doi.org/10.1212/01.WNL.0000161872.85903.8E] [PMID: 15911796]
[96]
Feldman B, Chapman J, Korczyn AD. Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson’s disease. Acta Neurol Scand 2006; 113(1): 14-7.
[http://dx.doi.org/10.1111/j.1600-0404.2005.00535.x] [PMID: 16367893]
[97]
Alexopoulos P, Richter-Schmidinger T, Horn M, et al. Hippocampal volume differences between healthy young apolipoprotein E ε2 and ε4 carriers. J Alzheimers Dis 2011; 26(2): 207-10.
[http://dx.doi.org/10.3233/JAD-2011-110356] [PMID: 21606569]
[98]
Yao N, Cheung C, Pang S, et al. Multimodal MRI of the hippocampus in Parkinson’s disease with visual hallucinations. Brain Struct Funct 2016; 221(1): 287-300.
[http://dx.doi.org/10.1007/s00429-014-0907-5] [PMID: 25287513]
[99]
Monsell SE, Besser LM, Heller KB, Checkoway H, Litvan I, Kukull WA. Clinical and pathologic presentation in Parkinson’s disease by apolipoprotein e4 allele status. Parkinsonism Relat Disord 2014; 20(5): 503-7.
[http://dx.doi.org/10.1016/j.parkreldis.2014.02.001] [PMID: 24582705]
[100]
Wang J, Si Y-M, Liu Z-L, Yu L. Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson’s disease. Pharmacogenetics 2003; 13(6): 365-9.
[http://dx.doi.org/10.1097/00008571-200306000-00008] [PMID: 12777967]
[101]
Crawley JN, Stivers JA, Blumstein LK, Paul SM. Cholecystokinin potentiates dopamine-mediated behaviors: Evidence for modulation specific to a site of coexistence. J Neurosci 1985; 5(8): 1972-83.
[http://dx.doi.org/10.1523/JNEUROSCI.05-08-01972.1985] [PMID: 4040554]
[102]
Papapetropoulos S, Farrer MJ, Stone JT, et al. Phenotypic associations of tau and ApoE in Parkinson’s disease. Neurosci Lett 2007; 414(2): 141-4.
[http://dx.doi.org/10.1016/j.neulet.2006.12.008] [PMID: 17204369]
[103]
Factor SA, Steenland NK, Higgins DS, et al. Disease-related and genetic correlates of psychotic symptoms in Parkinson’s disease. Mov Disord 2011; 26(12): 2190-5.
[http://dx.doi.org/10.1002/mds.23806] [PMID: 21714002]
[104]
Camicioli R, Rajput A, Rajput M, et al. Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson’s disease: Relationship to dementia and hallucinations. Mov Disord 2005; 20(8): 989-94.
[http://dx.doi.org/10.1002/mds.20481] [PMID: 15852364]
[105]
Goetz CG, Burke PF, Leurgans S, et al. Genetic variation analysis in parkinson disease patients with and without hallucinations: Case-control study. Arch Neurol 2001; 58(2): 209-13.
[http://dx.doi.org/10.1001/archneur.58.2.209] [PMID: 11176958]
[106]
Wang J, Zhao C, Chen B, Liu Z-L. Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson’s disease. Neurosci Lett 2004; 355(3): 193-6.
[http://dx.doi.org/10.1016/j.neulet.2003.11.006] [PMID: 14732464]
[107]
Puig MV, Gener T. Serotonin modulation of prefronto-hippocampal rhythms in health and disease. ACS Chem Neurosci 2015; 6(7): 1017-25.
[http://dx.doi.org/10.1021/cn500350e] [PMID: 25799292]
[108]
Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci 1997; 20(2): 92-8.
[http://dx.doi.org/10.1016/S0166-2236(96)10073-4] [PMID: 9023878]
[109]
Hoffmann M. The human frontal lobes and frontal network systems: An evolutionary, clinical, and treatment perspective. ISRN Neurol 2013; 2013: 892459.
[http://dx.doi.org/10.1155/2013/892459] [PMID: 23577266]
[110]
Drever BD, Riedel G, Platt B. The cholinergic system and hippocampal plasticity. Behav Brain Res 2011; 221(2): 505-14.
[http://dx.doi.org/10.1016/j.bbr.2010.11.037] [PMID: 21130117]
[111]
Couey JJ, Meredith RM, Spijker S, et al. Distributed network actions by nicotine increase the threshold for spike-timing-dependent plasticity in prefrontal cortex. Neuron 2007; 54(1): 73-87.
[http://dx.doi.org/10.1016/j.neuron.2007.03.006] [PMID: 17408579]
[112]
Kiernan JA. Anatomy of the temporal lobe. Epilepsy Res Treat 2012; 2012: 176157.
[http://dx.doi.org/10.1155/2012/176157] [PMID: 22934160]
[113]
Hepp DH, Foncke EMJ, Berendse HW, et al. Damaged fiber tracts of the nucleus basalis of Meynert in Parkinson’s disease patients with visual hallucinations. Sci Rep 2017; 7(1): 10112.
[http://dx.doi.org/10.1038/s41598-017-10146-y] [PMID: 28860465]
[114]
Perry EK, Perry RH. Acetylcholine and hallucinations: Disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 1995; 28(3): 240-58.
[http://dx.doi.org/10.1006/brcg.1995.1255] [PMID: 8546852]
[115]
Klinkenberg I, Sambeth A, Blokland A. Acetylcholine and attention. Behav Brain Res 2011; 221(2): 430-42.
[http://dx.doi.org/10.1016/j.bbr.2010.11.033] [PMID: 21108972]
[116]
Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord 2006; 21(11): 1899-907.
[http://dx.doi.org/10.1002/mds.21077] [PMID: 16960863]
[117]
Ogino S, Miyamoto S, Miyake N, Yamaguchi N. Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function. Psychiatry Clin Neurosci 2014; 68(1): 37-49.
[http://dx.doi.org/10.1111/pcn.12088] [PMID: 24102938]
[118]
Geyer MA, Vollenweider FX. Serotonin research: Contributions to understanding psychoses. Trends Pharmacol Sci 2008; 29(9): 445-53.
[http://dx.doi.org/10.1016/j.tips.2008.06.006] [PMID: 19086254]
[119]
Yasue I, Matsunaga S, Kishi T, Fujita K, Iwata N. Serotonin 2A Receptor inverse agonist as a treatment for Parkinson’s disease psychosis: A systematic review and meta-analysis of serotonin 2A receptor negative modulators. J Alzheimers Dis 2016; 50(3): 733-40.
[http://dx.doi.org/10.3233/JAD-150818] [PMID: 26757194]
[120]
Zhang G, Stackman RW Jr. The role of serotonin 5-HT2A receptors in memory and cognition. Front Pharmacol 2015; 6: 225.
[http://dx.doi.org/10.3389/fphar.2015.00225] [PMID: 26500553]
[121]
Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010; 67(4): 416-21.
[http://dx.doi.org/10.1001/archneurol.2010.35] [PMID: 20385906]
[122]
Huot P, Johnston TH, Darr T, et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord 2010; 25(10): 1399-408.
[http://dx.doi.org/10.1002/mds.23083] [PMID: 20629135]
[123]
Bortolozzi A, Díaz-Mataix L, Scorza MC, Celada P, Artigas F. The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem 2005; 95(6): 1597-607.
[http://dx.doi.org/10.1111/j.1471-4159.2005.03485.x] [PMID: 16277612]
[124]
Mocci G, Jiménez-Sánchez L, Adell A, Cortés R, Artigas F. Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action. Neuropharmacology 2014; 79: 49-58.
[http://dx.doi.org/10.1016/j.neuropharm.2013.10.021] [PMID: 24211653]
[125]
Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: Version III--the final common pathway. Schizophr Bull 2009; 35(3): 549-62.
[http://dx.doi.org/10.1093/schbul/sbp006] [PMID: 19325164]
[126]
Merritt K, McGuire P, Egerton A. Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis. Front Psychiatry 2013; 4: 151.
[http://dx.doi.org/10.3389/fpsyt.2013.00151] [PMID: 24324444]
[127]
Paz RD, Tardito S, Atzori M, Tseng KY. Glutamatergic dysfunction in schizophrenia: From basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol 2008; 18(11): 773-86.
[http://dx.doi.org/10.1016/j.euroneuro.2008.06.005] [PMID: 18650071]
[128]
Postma JU, Van Tilburg W. Visual hallucinations and delirium during treatment with amantadine (Symmetrel). J Am Geriatr Soc 1975; 23(5): 212-5.
[http://dx.doi.org/10.1111/j.1532-5415.1975.tb00187.x] [PMID: 123540]
[129]
Riederer P, Lange KW, Kornhuber J, Danielczyk W. Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia. Arzneimittelforschung 1992; 42(2A): 265-8.
[PMID: 1350197]
[130]
Pagonabarraga J, Soriano-Mas C, Llebaria G, López-Solà M, Pujol J, Kulisevsky J. Neural correlates of minor hallucinations in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord 2014; 20(3): 290-6.
[http://dx.doi.org/10.1016/j.parkreldis.2013.11.017] [PMID: 24373690]
[131]
Baglivo V, Cao B, Mwangi B, et al. Hippocampal subfield volumes in patients with first-episode psychosis. Schizophr Bull 2018; 44(3): 552-9.
[http://dx.doi.org/10.1093/schbul/sbx108] [PMID: 29897598]
[132]
Bilder RM, Bogerts B, Ashtari M, et al. Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia. Schizophr Res 1995; 17(1): 47-58.
[http://dx.doi.org/10.1016/0920-9964(95)00028-K] [PMID: 8541249]
[133]
Velasco M, Quintero JR, Castillo MC, et al. Excitotoxicity: An organized crime at the cellular level. J Neurol Neurosci 2017; 08(03): 1-10.
[http://dx.doi.org/10.21767/2171-6625.1000193]
[134]
Botha H, Carr J. Attention and visual dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 2012; 18(6): 742-7.
[http://dx.doi.org/10.1016/j.parkreldis.2012.03.004] [PMID: 22503538]
[135]
Oishi N, Udaka F, Kameyama M, Sawamoto N, Hashikawa K, Fukuyama H. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology 2005; 65(11): 1708-15.
[http://dx.doi.org/10.1212/01.wnl.0000187116.13370.e0] [PMID: 16344511]
[136]
Nagano-Saito A, Washimi Y, Arahata Y, et al. Visual hallucination in Parkinson’s disease with FDG PET. Mov Disord 2004; 19(7): 801-6.
[http://dx.doi.org/10.1002/mds.20129] [PMID: 15254938]
[137]
Shine JM, Halliday GM, Gilat M, et al. The role of dysfunctional attentional control networks in visual misperceptions in Parkinson’s disease. Hum Brain Mapp 2014; 35(5): 2206-19.
[http://dx.doi.org/10.1002/hbm.22321] [PMID: 23760982]
[138]
Gallagher DA, Parkkinen L, O’Sullivan SS, et al. Testing an aetiological model of visual hallucinations in Parkinson’s disease. Brain 2011; 134(Pt 11): 3299-309.
[http://dx.doi.org/10.1093/brain/awr225] [PMID: 21921019]
[139]
Papapetropoulos S, McCorquodale DS, Gonzalez J, Jean-Gilles L, Mash DC. Cortical and amygdalar Lewy body burden in Parkinson’s disease patients with visual hallucinations. Parkinsonism Relat Disord 2006; 12(4): 253-6.
[http://dx.doi.org/10.1016/j.parkreldis.2005.10.005] [PMID: 16368258]
[140]
Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125(Pt 2): 391-403.
[http://dx.doi.org/10.1093/brain/awf033] [PMID: 11844739]
[141]
Rasmussen NB, Olesen MV, Brudek T, et al. 5-HT2A receptor binding in the frontal cortex of Parkinson’s disease patients and alpha-synuclein overexpressing mice: a postmortem study. Park Dis 2016; 2016: 3682936.
[http://dx.doi.org/10.1155/2016/3682936] [PMID: 27579212]
[142]
Jacobson SA, Morshed T, Dugger BN, et al. Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. Parkinsonism Relat Disord 2014; 20(9): 1009-14.
[http://dx.doi.org/10.1016/j.parkreldis.2014.06.018] [PMID: 25027359]
[143]
Shomstein S. Cognitive functions of the posterior parietal cortex: Top-down and bottom-up attentional control. Front Integr Nuerosci 2012; 6: 38.
[http://dx.doi.org/10.3389/fnint.2012.00038] [PMID: 22783174]
[144]
Ibarretxe-Bilbao N, Ramirez-Ruiz B, Junque C, et al. Differential progression of brain atrophy in Parkinson’s disease with and without visual hallucinations. J Neurol Neurosurg Psychiatry 2010; 81(6): 650-7.
[http://dx.doi.org/10.1136/jnnp.2009.179655] [PMID: 19965847]
[145]
Kurita A, Murakami M, Takagi S, Matsushima M, Suzuki M. Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies. Mov Disord 2010; 25(2): 167-71.
[http://dx.doi.org/10.1002/mds.22919] [PMID: 20063433]
[146]
Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2001; 70(6): 734-8.
[http://dx.doi.org/10.1136/jnnp.70.6.734] [PMID: 11385005]
[147]
Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson’s disease: Prevalence, phenomenology and risk factors. Brain 2000; 123(Pt 4): 733-45.
[http://dx.doi.org/10.1093/brain/123.4.733] [PMID: 10734005]
[148]
Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: Report of an NINDS, NIMH work group. Mov Disord 2007; 22(8): 1061-8.
[http://dx.doi.org/10.1002/mds.21382] [PMID: 17266092]
[149]
Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson’s disease. Clin Neuropharmacol 1998; 21(5): 289-95.
[PMID: 9789709]
[150]
Hepp DH, Foncke EMJ, Olde Dubbelink KTE, van de Berg WDJ, Berendse HW, Schoonheim MM. Loss of functional connectivity in patients with parkinson disease and visual hallucinations. Radiology 2017; 285(3): 896-903.
[http://dx.doi.org/10.1148/radiol.2017170438] [PMID: 28952907]
[151]
Lenka A, Herath P, Christopher R, Pal PK. Psychosis in Parkinson’s disease: From the soft signs to the hard science. J Neurol Sci 2017; 379: 169-76.
[http://dx.doi.org/10.1016/j.jns.2017.06.011] [PMID: 28716235]
[152]
Goldman JG, Stebbins GT, Dinh V, et al. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson’s disease with hallucinations. Brain 2014; 137(Pt 3): 849-59.
[http://dx.doi.org/10.1093/brain/awt360] [PMID: 24480486]
[153]
Collerton D, Perry E, McKeith I. Why people see things that are not there: A novel Perception and Attention Deficit model for recurrent complex visual hallucinations. Behav Brain Sci 2005; 28(6): 737-57.
[http://dx.doi.org/10.1017/S0140525X05000130] [PMID: 16372931]
[154]
Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: An fMRI study. Neurology 2004; 63(8): 1409-16.
[http://dx.doi.org/10.1212/01.WNL.0000141853.27081.BD] [PMID: 15505157]
[155]
Lee J-Y, Kim JM, Ahn J, Kim H-J, Jeon BS, Kim TW. Retinal nerve fiber layer thickness and visual hallucinations in Parkinson’s Disease. Mov Disord 2014; 29(1): 61-7.
[http://dx.doi.org/10.1002/mds.25543] [PMID: 23775932]
[156]
Lee J-Y, Yoon EJ, Lee WW, Kim YK, Lee J-Y, Jeon B. Lateral geniculate atrophy in Parkinson’s with visual hallucination: A trans-synaptic degeneration? Mov Disord 2016; 31(4): 547-54.
[http://dx.doi.org/10.1002/mds.26533] [PMID: 26846525]
[157]
Holroyd S, Wooten GF. Preliminary FMRI evidence of visual system dysfunction in Parkinson’s disease patients with visual hallucinations. J Neuropsychiatry Clin Neurosci 2006; 18(3): 402-4.
[http://dx.doi.org/10.1176/jnp.2006.18.3.402] [PMID: 16963591]
[158]
Pacchetti C, Manni R, Zangaglia R, et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson’s disease. Mov Disord 2005; 20(11): 1439-48.
[http://dx.doi.org/10.1002/mds.20582] [PMID: 16028215]
[159]
Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson’s disease: A review. Drugs Aging 2008; 25(8): 665-82.
[http://dx.doi.org/10.2165/00002512-200825080-00004] [PMID: 18665659]
[160]
Barrett MJ, Smolkin ME, Flanigan JL, Shah BB, Harrison MB, Sperling SA. Characteristics, correlates, and assessment of psychosis in Parkinson disease without dementia. Parkinsonism Relat Disord 2017; 43: 56-60.
[http://dx.doi.org/10.1016/j.parkreldis.2017.07.011] [PMID: 28735797]
[161]
Högl B, Stefani A. REM sleep behavior disorder (RBD): Update on diagnosis and treatment. Somnologie (Berl) 2017; 21(S1): 1-8.
[http://dx.doi.org/10.1007/s11818-016-0048-6] [PMID: 28163603]
[162]
Manni R, Terzaghi M, Ratti P-L, Repetto A, Zangaglia R, Pacchetti C. Hallucinations and REM sleep behaviour disorder in Parkinson’s disease: Dream imagery intrusions and other hypotheses. Conscious Cogn 2011; 20(4): 1021-6.
[http://dx.doi.org/10.1016/j.concog.2010.10.009] [PMID: 21071244]
[163]
Boeve BF, Silber MH, Ferman TJ, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med 2013; 14(8): 754-62.
[http://dx.doi.org/10.1016/j.sleep.2012.10.015] [PMID: 23474058]
[164]
Postuma RB, Adler CH, Dugger BN, et al. REM sleep behavior disorder and neuropathology in Parkinson’s disease. Mov Disord 2015; 30(10): 1413-7.
[http://dx.doi.org/10.1002/mds.26347] [PMID: 26265105]
[165]
Iranzo A, Fernández-Arcos A, Tolosa E, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: Study in 174 patients. PLoS One 2014; 9(2): e89741.
[http://dx.doi.org/10.1371/journal.pone.0089741] [PMID: 24587002]
[166]
Geddes MR, Tie Y, Gabrieli JDE, McGinnis SM, Golby AJ, Whitfield-Gabrieli S. Altered functional connectivity in lesional peduncular hallucinosis with REM sleep behavior disorder. Cortex J Devoted Study Nerv Syst Behav 2016; 74: 96-106.
[http://dx.doi.org/10.1016/j.cortex.2015.10.015] [PMID: 26656284]
[167]
Lenka A, Hegde S, Jhunjhunwala KR, Pal PK. Interactions of visual hallucinations, rapid eye movement sleep behavior disorder and cognitive impairment in Parkinson’s disease: A review. Parkinsonism Relat Disord 2016; 22: 1-8.
[http://dx.doi.org/10.1016/j.parkreldis.2015.11.018] [PMID: 26639978]
[168]
Wood LD, Neumiller JJ, Setter SM, Dobbins EK. Clinical review of treatment options for select nonmotor symptoms of Parkinson’s disease. Am J Geriatr Pharmacother 2010; 8(4): 294-315.
[http://dx.doi.org/10.1016/j.amjopharm.2010.08.002] [PMID: 20869620]
[169]
Henderson MJ, Mellers JDC. Psychosis in Parkinson’s disease: ‘between a rock and a hard place. Int Rev Psychiatry 2009; 12(4): 319.
[170]
Fernandez HH, Trieschmann ME, Okun MS. Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson’s disease. Mov Disord 2005; 20(1): 104-5.
[http://dx.doi.org/10.1002/mds.20260] [PMID: 15390047]
[171]
Du M, Wang X, Yin S, et al. De-escalation techniques for psychosis-induced aggression or agitation. Cochrane Database Syst Rev 2017; 4(4): CD009922.
[http://dx.doi.org/10.1002/14651858.CD009922.pub2] [PMID: 28368091]
[172]
Van Rompaey B, Elseviers MM, Van Drom W, Fromont V, Jorens PG. The effect of earplugs during the night on the onset of delirium and sleep perception: A randomized controlled trial in intensive care patients. Crit Care 2012; 16(3): R73.
[http://dx.doi.org/10.1186/cc11330] [PMID: 22559080]
[173]
Patel J, Baldwin J, Bunting P, Laha S. The effect of a multicomponent multidisciplinary bundle of interventions on sleep and delirium in medical and surgical intensive care patients. Anaesthesia 2014; 69(6): 540-9.
[http://dx.doi.org/10.1111/anae.12638] [PMID: 24813132]
[174]
Meagher DJ. Delirium: Optimising management. BMJ 2001; 322(7279): 144-9.
[http://dx.doi.org/10.1136/bmj.322.7279.144] [PMID: 11159573]
[175]
Black KJ. Treatment of Parkinson’s disease psychosis. Med Int Rev 2017; 27(109): 266-71.
[PMID: 30140115]
[176]
Shin H-W, Chung SJ. Drug-induced parkinsonism. J Clin Neurol 2012; 8(1): 15-21.
[http://dx.doi.org/10.3988/jcn.2012.8.1.15] [PMID: 22523509]
[177]
Haidary HA, Padhy RK. Clozapine. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, Florida 2021. Available from: www.ncbi.nlm.nih.gov/books/NBK535399/
[178]
Haidary HA, Stępnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Molecules 2018; 23(8): E2087.
[http://dx.doi.org/10.3390/molecules23082087] [PMID: 30127324]
[179]
Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: A randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004; 75(5): 689-95.
[http://dx.doi.org/10.1136/jnnp.2003.029868] [PMID: 15090561]
[180]
Zhang H, Wang L, Fan Y, et al. Atypical antipsychotics for Parkinson’s disease psychosis: A systematic review and meta-analysis. Neuropsychiatr Dis Treat 2019; 15: 2137-49.
[http://dx.doi.org/10.2147/NDT.S201029] [PMID: 31551655]
[181]
Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004; 27(4): 153-6.
[http://dx.doi.org/10.1097/01.wnf.0000136891.17006.ec] [PMID: 15319699]
[182]
Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: Quetiapine versus clozapine for Parkinson’s disease psychosis. Clin Neuropharmacol 2006; 29(6): 331-7.
[http://dx.doi.org/10.1097/01.WNF.0000236769.31279.19] [PMID: 17095896]
[183]
Shotbolt P, Samuel M, Fox C, David AS. A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease. Neuropsychiatr Dis Treat 2009; 5: 327-32.
[http://dx.doi.org/10.2147/NDT.S5335] [PMID: 19557142]
[184]
Nichols MJ, Hartlein JM, Eicken MG, Racette BA, Black KJ. A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease. F1000 Res 2013; 2: 150.
[http://dx.doi.org/10.12688/f1000research.2-150.v1] [PMID: 24627787]
[185]
Chen JJ. Treatment of psychotic symptoms in patients with Parkinson disease. Ment Health Clin 2018; 7(6): 262-70.
[http://dx.doi.org/10.9740/mhc.2017.11.262] [PMID: 29955532]
[186]
Pintor L, Valldeoriola F, Baillés E, Martí MJ, Muñiz A, Tolosa E. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: A randomized open clinical trial. Clin Neuropharmacol 2012; 35(2): 61-6.
[http://dx.doi.org/10.1097/WNF.0b013e31824d5115] [PMID: 22388466]
[187]
Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002; 17(5): 1031-5.
[http://dx.doi.org/10.1002/mds.10217] [PMID: 12360554]
[188]
Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry 2002; 52(5): 438-45.
[http://dx.doi.org/10.1016/S0006-3223(02)01392-6] [PMID: 12242060]
[189]
Meco G, Alessandri A, Giustini P, Bonifati V. Risperidone in levodopa-induced psychosis in advanced Parkinson’s disease: An open-label, long-term study. Mov Disord 1997; 12(4): 610-2.
[http://dx.doi.org/10.1002/mds.870120423] [PMID: 9251085]
[190]
Ellis T, Cudkowicz ME, Sexton PM, Growdon JH. Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2000; 12(3): 364-9.
[http://dx.doi.org/10.1176/jnp.12.3.364] [PMID: 10956570]
[191]
Mohr E, Mendis T, Hildebrand K, De Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson’s disease: An open pilot trial. Mov Disord 2000; 15(6): 1230-7.
[http://dx.doi.org/10.1002/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9] [PMID: 11104211]
[192]
Abbas A, Roth BL. Pimavanserin tartrate: A 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother 2008; 9(18): 3251-9.
[http://dx.doi.org/10.1517/14656560802532707] [PMID: 19040345]
[193]
Vanover KE, Weiner DM, Makhay M, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 2006; 317(2): 910-8.
[http://dx.doi.org/10.1124/jpet.105.097006] [PMID: 16469866]
[194]
Espay AJ, Guskey MT, Norton JC, et al. Pimavanserin for Parkinson’s Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. Mov Disord 2018; 33(11): 1769-76.
[http://dx.doi.org/10.1002/mds.27488] [PMID: 30387904]
[195]
Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson’s disease psychosis. Neuropsychopharmacology 2010; 35(4): 881-92.
[http://dx.doi.org/10.1038/npp.2009.176] [PMID: 19907417]
[196]
Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: A randomised, placebo-controlled phase 3 trial. Lancet 2014; 383(9916): 533-40.
[http://dx.doi.org/10.1016/S0140-6736(13)62106-6] [PMID: 24183563]
[197]
Tampi RR, Tampi DJ, Young JJ, Balachandran S, Hoq RA, Manikkara G. Evidence for using pimavanserin for the treatment of Parkinson’s disease psychosis. World J Psychiatry 2019; 9(3): 47-54.
[http://dx.doi.org/10.5498/wjp.v9.i3.47] [PMID: 31211112]
[198]
Dedic N, Jones PG, Hopkins SC, et al. SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action. J Pharmacol Exp Ther 2019; 371(1): 1-14.
[http://dx.doi.org/10.1124/jpet.119.260281] [PMID: 31371483]
[199]
Savitt J, Aouchiche R. Management of visual dysfunction in patients with Parkinson’s disease. J Parkinsons Dis 2020; 10(s1): S49-56.
[http://dx.doi.org/10.3233/JPD-202103] [PMID: 32741840]
[200]
Sunovion. A study to evaluate the efficacy, safety and tolerability of SEP-363856 in subjects with Parkinson’s disease psychosis. Report No.: NCT02969369. Available from: https://clinicaltrials.gov/ct2/show/NCT02969369
[201]
King’s College London. SRC inhibition as a potential target for Parkinson’s disease psychosis (SCRIPT). Report No.: NCT03661125. Available from: https://clinicaltrials.gov/ct2/show/NCT03661125
[202]
Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol 2009; 23(8): 979-83.
[http://dx.doi.org/10.1177/0269881108096519] [PMID: 18801821]
[203]
Davies C, Bhattacharyya S. Cannabidiol as a potential treatment for psychosis. Ther Adv Psychopharmacol 2019; 9: 2045125319881916.
[http://dx.doi.org/10.1177/2045125319881916] [PMID: 31741731]
[204]
Schubart CD, Sommer IEC, Fusar-Poli P, de Witte L, Kahn RS, Boks MPM. Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 2014; 24(1): 51-64.
[http://dx.doi.org/10.1016/j.euroneuro.2013.11.002] [PMID: 24309088]
[205]
Moreira FA, Guimarães FS. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 2005; 512(2-3): 199-205.
[http://dx.doi.org/10.1016/j.ejphar.2005.02.040] [PMID: 15840405]
[206]
Fernández-Ruiz J, Sagredo O, Pazos MR, et al. Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol 2013; 75(2): 323-33.
[http://dx.doi.org/10.1111/j.1365-2125.2012.04341.x] [PMID: 22625422]
[207]
Chagas MHN, Zuardi AW, Tumas V, et al. Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial. J Psychopharmacol 2014; 28(11): 1088-98.
[http://dx.doi.org/10.1177/0269881114550355] [PMID: 25237116]
[208]
French ED, Dillon K, Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 1997; 8(3): 649-52.
[http://dx.doi.org/10.1097/00001756-199702100-00014] [PMID: 9106740]
[209]
Diana M, Melis M, Gessa GL. Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur J Neurosci 1998; 10(9): 2825-30.
[http://dx.doi.org/10.1111/j.1460-9568.1998.00292.x] [PMID: 9758152]
[210]
Zuardi AW, Rodrigues JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl) 1991; 104(2): 260-4.
[http://dx.doi.org/10.1007/BF02244189] [PMID: 1678894]
[211]
Pagano G, Rengo G, Pasqualetti G, et al. Cholinesterase inhibitors for Parkinson’s disease: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2015; 86(7): 767-73.
[http://dx.doi.org/10.1136/jnnp-2014-308764] [PMID: 25224676]
[212]
Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry 2004; 19(1): 1-8.
[http://dx.doi.org/10.1002/gps.993] [PMID: 14716693]
[213]
Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol Sci 2002; 23(1): 41-3.
[http://dx.doi.org/10.1007/s100720200022] [PMID: 12111620]
[214]
Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial. Mov Disord 2001; 16(6): 1171-4.
[http://dx.doi.org/10.1002/mds.1204] [PMID: 11748755]
[215]
Richard IH, Justus AW, Greig NH, Marshall F, Kurlan R. Worsening of motor function and mood in a patient with Parkinson’s disease after pharmacologic challenge with oral rivastigmine. Clin Neuropharmacol 2002; 25(6): 296-9.
[http://dx.doi.org/10.1097/00002826-200211000-00002] [PMID: 12469000]
[216]
Tsai C-H, Huang H-C, Liu B-L, et al. Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson’s disease with dementia. Psychiatry Clin Neurosci 2014; 68(9): 692-700.
[http://dx.doi.org/10.1111/pcn.12175] [PMID: 24612097]
[217]
Di Rocco A, Rogers JD, Brown R, Werner P, Bottiglieri T. S-Adenosyl-Methionine improves depression in patients with Parkinson’s disease in an open-label clinical trial. Mov Disord 2000; 15(6): 1225-9.
[http://dx.doi.org/10.1002/1531-8257(200011)15:6<1225::AID-MDS1025>3.0.CO;2-A] [PMID: 11104210]
[218]
Strous RD, Ritsner MS, Adler S, et al. Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophrenia. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 2009; 19(1): 14-22.
[http://dx.doi.org/10.1016/j.euroneuro.2008.08.004] [PMID: 18824331]
[219]
Spencer R, Serumaga B. Prescribing antiemetics for patients with Parkinson’s. Prescriber 2011; 22(18): 48-9.
[http://dx.doi.org/10.1002/psb.804]
[220]
Zoldan J, Friedberg G, Goldberg-Stern H, Melamed E. Ondansetron for hallucinosis in advanced Parkinson’s disease. Lancet 1993; 341(8844): 562-3.
[http://dx.doi.org/10.1016/0140-6736(93)90327-D] [PMID: 8094803]
[221]
Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson’s disease: Treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995; 45(7): 1305-8.
[http://dx.doi.org/10.1212/WNL.45.7.1305] [PMID: 7617188]
[222]
Eichhorn TE, Brunt E, Oertel WH. Ondansetron treatment of L-dopa-induced psychosis. Neurology 1996; 47(6): 1608-9.
[http://dx.doi.org/10.1212/WNL.47.6.1608-b] [PMID: 8960764]
[223]
Tampi RR, Maksimowski M, Lingamchetty T, Farheen SA. Is ondansetron beneficial for psychosis associated with dementia? Ann Clin Psychiatry 2018; 30(3): 200-6.
[PMID: 30028894]
[224]
Muralidharan K, Thimmaiah R, Chakraborty V, Jain S. Bifrontal ECT for drug-induced psychosis in Parkinson’s disease. Indian J Psychiatry 2011; 53(2): 156-8.
[http://dx.doi.org/10.4103/0019-5545.82549] [PMID: 21772651]
[225]
Ueda S, Koyama K, Okubo Y. Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT 2010; 26(2): 111-5.
[http://dx.doi.org/10.1097/YCT.0b013e3181c18a3d] [PMID: 20386461]
[226]
Usui C, Hatta K, Doi N, et al. Improvements in both psychosis and motor signs in Parkinson’s disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(7): 1704-8.
[http://dx.doi.org/10.1016/j.pnpbp.2011.05.003] [PMID: 21605615]
[227]
Baldinger P, Lotan A, Frey R, Kasper S, Lerer B, Lanzenberger R. Neurotransmitters and electroconvulsive therapy. J ECT 2014; 30(2): 116-21.
[http://dx.doi.org/10.1097/YCT.0000000000000138] [PMID: 24820941]
[228]
Popeo D, Kellner CH. ECT for Parkinson’s disease. Med Hypotheses 2009; 73(4): 468-9.
[http://dx.doi.org/10.1016/j.mehy.2009.06.053] [PMID: 19660875]
[229]
Kennedy R, Mittal D, O’Jile J. Electroconvulsive therapy in movement disorders: An update. J Neuropsychiatry Clin Neurosci 2003; 15(4): 407-21.
[http://dx.doi.org/10.1176/jnp.15.4.407] [PMID: 14627767]
[230]
Calderón-Fajardo H, Cervantes-Arriaga A, Llorens-Arenas R, Ramírez-Bermudez J, Ruiz-Chow Á, Rodríguez-Violante M. Electroconvulsive therapy in Parkinson’s disease. Arq Neuropsiquiatr 2015; 73(10): 856-60.
[http://dx.doi.org/10.1590/0004-282X20150131] [PMID: 26331387]
[231]
Sadananda SK, Holla B, Viswanath B, et al. Effectiveness of electroconvulsive therapy for drug-induced parkinsonism in the elderly. J ECT 2013; 29(1): e6-7.
[http://dx.doi.org/10.1097/YCT.0b013e3182611563] [PMID: 23422531]
[232]
Nishioka K, Tanaka R, Shimura H, Hirano K, Hatano T, Miyakawa K, et al. Quantitative evaluation of electroconvulsive therapy for Parkinson’s disease with refractory psychiatric symptoms. J Neural Transm Vienna Austria 1996 2014; 121(11): 1405.
[233]
Brys M, Fox MD, Agarwal S, et al. Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: A randomized trial. Neurology 2016; 87(18): 1907-15.
[http://dx.doi.org/10.1212/WNL.0000000000003279] [PMID: 27708129]
[234]
Rektorová I, Anderková Ľ. Noninvasive brain stimulation and implications for nonmotor symptoms in Parkinson’s disease. Int Rev Neurobiol 2017; 134: 1091-110.
[http://dx.doi.org/10.1016/bs.irn.2017.05.009] [PMID: 28805565]
[235]
Camprodon JA, Pascual-Leone A. Multimodal applications of transcranial magnetic stimulation for circuit-based psychiatry. JAMA Psychiatry 2016; 73(4): 407-8.
[http://dx.doi.org/10.1001/jamapsychiatry.2015.3127] [PMID: 26981644]
[236]
Ghanbari Jolfaei A, Naji B, Nasr Esfehani M. Repetitive transcranial magnetic stimulation in resistant visual hallucinations in a woman with schizophrenia: A case report. Iran J Psychiatry Behav Sci 2016; 10(1): e3561.
[http://dx.doi.org/10.17795/ijpbs-3561] [PMID: 27284279]
[237]
Blom JD, Looijestijn J, Goekoop R, et al. Treatment of Alice in wonderland syndrome and verbal auditory hallucinations using repetitive transcranial magnetic stimulation: a case report with fmri findings. Psychopathology 2011; 44(5): 337-44.
[http://dx.doi.org/10.1159/000325102] [PMID: 21734437]
[238]
Hanoğlu T, Hanoğlu L, Güntekin B, Aktürk T, Yulug B. The therapeutic role of repetitive transcranial magnetic stimulation (rTMS) in parkinsonian visual hallucinations: Electrophysiological correlates. J Clin Neurosci 2019; 69: 281-4.
[http://dx.doi.org/10.1016/j.jocn.2019.08.002] [PMID: 31477464]
[239]
Elder GJ, Colloby SJ, Firbank MJ, McKeith IG, Taylor J-P. Consecutive sessions of transcranial direct current stimulation do not remediate visual hallucinations in Lewy body dementia: A randomised controlled trial. Alzheimers Res Ther 2019; 11(1): 9.
[http://dx.doi.org/10.1186/s13195-018-0465-9] [PMID: 30658705]
[240]
ACADIA Pharmaceuticals Inc. The INSYTE (management of Parkinson’s Disease Psychosis in Actual Practice) Study. Report No.: NCT03152292. Available from: https://clinicaltrials.gov/ct2/show/NCT03152292
[241]
ACADIA Pharmaceuticals Inc. Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson’s Disease Psychosis Report No: NCT04292223 Available from: https://clinicaltrials.gov/ct2/show/NCT04292223

Rights & Permissions Print Cite
Article Metrics
4
© 2024 Bentham Science Publishers | Privacy Policy